

**Box No. VIII(iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America).**  
 The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VII, VII(I) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

**Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))  
 for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. PCT/EP2005/001939 (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications: \_\_\_\_\_

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: EATHERTON, Andrew John

Residence: Harlow, Essex, United Kingdom

(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709

Citizenship: GB

Inventor's Signature: ax lecter  
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 23<sup>rd</sup> May 2005

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: GIBLIN, Gerard Martin Paul

Residence: Harlow, Essex, United Kingdom

(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709

Citizenship: GB

Inventor's Signature: Giblin  
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 24 May 2005  
 (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

**Continuation of Box No. VIII(i) to (v) Declaration**

If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII(iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: MITCHELL, William Leonard

Residence: Harlow, Essex, United Kingdom

(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709

Citizenship: GB

*W.L. Mitchell*

Inventor's Signature:

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 24 May 2005

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: NAYLOR, Alan

Residence: Harlow, Essex, United Kingdom

(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709

Citizenship: GB

Inventor's Signature:

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 3rd June 2005

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

**Box No. VIII(ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT**

The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII(I) to (v) (in general and the specific Notes to Box No. VIII(ii)). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

in relation to international application No. PCT/EP2005/001939

GLAXO GROUP LIMITED is entitled to apply for and be granted a patent by virtue of the following:

- (i) transfer of entitlement from inventors EATHERTON, Andrew John, GIBLIN, Gerard Martin Paul, MITCHELL, William Leonard, and NAYLOR, Alan to GlaxoSmithKline Services Unlimited by way of employment contract
- (ii) an assignment from GlaxoSmithKline Services Unlimited to Glaxo Group Limited effective 23 February 2004

This declaration is made for the purposes of all designations except the designation of the United States of America.

This declaration is continued on the following sheet, "Continuation of Box No. VIII(ii)".

Form PCT/RO/101 (declaration sheet (ii)) (March 2001; reprint January 2003)

See Notes to the request form

**Box No. VIII(iii) DECLARATION: ENTITLEMENT TO CLAIM PRIORITY**

The declaration must conform to the standardized wording provided for in Section 213; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII(iii) and 51bis.1(a)(iii)

Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application specified below, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii)):

in relation to international application No. PCT/EP2005/001939

GLAXO GROUP LIMITED is entitled to claim priority of earlier application No.s 0403998.8 and 0425071.8 filed in the United Kingdom by virtue of the following:

- (I) transfer of entitlement from inventors EATHERTON, Andrew John, GIBLIN, Gerard Martin Paul, MITCHELL, William Leonard, and NAYLOR, Alan to GlaxoSmithKline Services Unlimited by way of employment contract
- (II) an assignment from GlaxoSmithKline Services Unlimited to Glaxo Group Limited effective **23 February 2004**

This declaration is made for the purposes of all designations, except the designation of the United States of America.

This declaration is continued on the following sheet, "Continuation of Box No. VIII(iii)".

Form PCT/RO/101 (declaration sheet (iii)) (March 2001; reprint January 2003)

See Notes to the request form